These can include any of the following: Age: It is more common for people over age 65 to have kidney or liver issues, and this can affect how the medication is metabolized or processed in the body and how much of it becomes available to use
GLP-1 agonists are currently approved for three conditions: type 2 diabetes, obesity, and heart disease
BMI thresholds, documented failure of cheaper meds, etc.) and (b) manage utilization to prevent misuse
Tirzepatide is sold as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes, working as a dual GLP-1/GIP receptor agonist that targets both the GLP-1 and GIP receptors instead of GLP-1 alone, which enhances fat metabolism and insulin sensitivity beyond a single-receptor peptide
In our excitement for treating obesity, were going to trade it for sarcopenia, she says
What Is the Medicare GLP-1 Bridge